Page 13 - Peter Stein News Today

After some 40 years behind the lens, independent filmmaker Peter Stein stepped out in front of the camera recently to be a contestant on the popular TV quiz show "Jeopardy!"

After some 40 years behind the lens, independent filmmaker Peter Stein stepped out in front of the camera recently to be a contestant on the popular TV quiz show "Jeopardy!"

Biogen Inc noted delayed uptake of its Alzheimer’s drug, Aduhelm, in the US, but said it continues to believe in the treatment’s long-term potential.

Stockholder Peter Stein has filed a class action complaint against Adesto Technologies for violating the Securities Exchange Act of 1934. The complaint

Wednesday, August 4, 2021 Has the Food and Drug Administration (FDA) finally ushered in a new era for the U.S. biosimilar marketplace? Many in the industry are hopeful after the Agency approved its first interchangeable biosimilar, Mylan’s Semglee (insulin glargine) on July 28, 2021. Mylan’s Semglee is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. ...

By Bill Galluccio Photo: Getty Images The U.S. Food and Drug Administration announced that it has approved the first interchangeable biosimilar insulin product. The approval will allow pharmacists to automatically swap out expensive, brand-name insulin with the cheaper generic version. The FDA said that the biosimilar drug Semglee is interchangeable with Lantus, a widely prescribed insulin analog. Before the FDA approved Semglee, a doctor had to specifically prescribe a generic brand of insul...

Semglee Approved as First Interchangeable Biosimilar Insulin Product Credit: Biocon Biologics The Food and Drug Administration (FDA) has approved Semglee ® (insulin glargine-yfgn injection) as the first interchangeable biosimilar insulin product indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Semglee is a long-acting human insulin analogue that has an identical amino acid sequence to Lant...

First interchangeable biosimilar insulin product approved by FDA for treatment of diabetes Today, the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus. Semglee (insulin glargine-yfgn) is both biosimilar to, and interchangeable with (can be substituted for), its reference product Lantus (insulin glargine),...

The controversial approval of an Alzheimer’s drug reignites the battle over the underlying cause of the disease Laurie McGinley © Jessica Rinaldi/Pool/Via Reuters Marc Archambault, who has early-stage Alzheimers disease, receives his first dose Wednesday of the newly approved intravenous drug Aduhelm at Butler Hospital in Providence, R.I. (Jessica Rinaldi/Pool/Reuters) Neurologist Matthew S. Schrag was surprised when he heard the Food and Drug Administration had approved ...

US lawmakers launch investigation into the controversial FDA approval of the first Alzheimers drug since 2003 and why it costs $56,000 The House Committee on Oversight and Reform and the House Committee on Energy and Commerce launch investigation into the controversial approval of Aduhelm The drug received approval despite mixed clinical trials results, though it did show it could potentially reduce cognitive decline by 22% Lawmakers are concerned about the drugs steep price tag, that will cost...